<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457467</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-BC-20170323</org_study_id>
    <nct_id>NCT03457467</nct_id>
  </id_info>
  <brief_title>Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer</brief_title>
  <official_title>Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yan Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of the patients with metastatic breast cancer remains a major problem. However,
      there is an intermediate state between the primary tumor and distant metastases called
      oligometastasis. Current research indicates that good local control of oligometastasis can be
      obtained with Stereotactic body radiotherapy (SBRT) Can not prolong the long-term survival of
      patients. Researchers believe that after SBRT treatment of patients with oligometacosis in
      breast cancer, it is necessary to explore whether the anti-angiogenic therapy targeted drug
      apatinib can reduce the occurrence of new lesions and prolong the survival of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of the patients with metastatic breast cancer remains a major problem. However,
      there is an intermediate state between the primary tumor and distant metastases called
      oligometastasis. Current research indicates that good local control of oligometastasis can be
      obtained with Stereotactic body radiotherapy (SBRT) Can not prolong the long-term survival of
      patients. Researchers believe that after SBRT treatment of patients with oligometacosis in
      breast cancer. So, through the detection of microRNA in the primary lesion of breast cancer
      patients with oligometastasis to screen the patients with oligomerization and potential
      multiple metastases; explore the existing medical treatment, based on the control of local
      lesions by SBRT, the use of apatinib anti-angiogenic targeted maintenance therapy, with a
      view to reducing the incidence of new lesions, thereby prolonging the patient's survival.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 3 year</time_frame>
    <description>OS is defined as the length of time from random assignment to death or to last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Approximately 2 year</time_frame>
    <description>time from randomization to documented progressive disease or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events(AEs)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT+apatinib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity</description>
    <arm_group_label>SBRT+apatinib group</arm_group_label>
    <other_name>Apatinib Mesylate Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment</description>
    <arm_group_label>SBRT+apatinib group</arm_group_label>
    <other_name>Stereotactic body radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age: ≥ 18 years old women; 2. Histologically confirmed breast cancer; 3 weeks before
        enrollment ECOG PS score: 0-2 points; 4. systemic metastasis lesions ≤ 5, Stereotactic body
        radiotherapy before receiving medical treatment to achieve partial relief or stable
        disease; 5. Appropriate hematological parameters and liver and kidney function: absolute
        neutrophil ≧ 1.5 × 109 / L; platelet count ≧ 75 × 109 / L; serum total bilirubin ≦ 1.5 ×
        upper limit of normal; AST and ALT ≦ 2.5 × upper limit of normal (if liver dysfunction) 6.
        Subject voluntarily joined the study and signed the informed consent form.

        Exclusion Criteria:

          1. After the above image examination of the whole body metastasis lesions ≥ 6;

          2. Have received one or more palliative chemotherapy regulators failed;

          3. Patients with a high risk of bleeding: active gastric digestive ulcer in the stomach
             with fecal occult blood (++); those with a history of melena and / or vomiting within
             3 months; persons with abnormal coagulation and bleeding tendency; 3-4 grade
             hypertension patients;

        5. Renal insufficiency 3 and above patients; 6. Hand-foot syndrome ≥ 3 or more patients; 7.
        There are uncontrolled concomitant diseases in the first 6 months of the study, including
        unstable angina pectoris, acute myocardial infarction, cerebrovascular accident and so on;
        8. Pregnant or breastfeeding patients, or who have fertility without taking contraceptive
        measures; 9. A history of malignancy, but disease-free survival of more than 5 years; 10.
        Concurrent with other anti-cancer therapies or other interventional clinical trials; 11.
        Patients unable to follow the study due to psychological, family-living social reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Li</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Li</last_name>
    <phone>18980606860</phone>
    <email>yy1240@163.com</email>
  </overall_contact>
  <reference>
    <citation>Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol. 1994 Oct;12(10):2229-34. Review.</citation>
    <PMID>7931493</PMID>
  </reference>
  <reference>
    <citation>Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009 Jun;115(3):601-8. doi: 10.1007/s10549-008-0157-4. Epub 2008 Aug 22.</citation>
    <PMID>18719992</PMID>
  </reference>
  <reference>
    <citation>Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010 Jan;7(1):44-54. doi: 10.1038/nrclinonc.2009.188. Epub 2009 Dec 8. Review. Erratum in: Nat Rev Clin Oncol. 2010 Aug;7(8):422. Dosage error in article text.</citation>
    <PMID>19997074</PMID>
  </reference>
  <reference>
    <citation>Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forquer JA, Papiez L, McGarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD. Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther. 2009 May;9(5):621-35. doi: 10.1586/era.09.15. Review. Erratum in: Expert Rev Anticancer Ther. 2009 Sep;9(9):1348.</citation>
    <PMID>19445579</PMID>
  </reference>
  <reference>
    <citation>Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6(12):e28650. doi: 10.1371/journal.pone.0028650. Epub 2011 Dec 13.</citation>
    <PMID>22174856</PMID>
  </reference>
  <reference>
    <citation>Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One. 2010 Oct 4;5(10). pii: e13176. doi: 10.1371/journal.pone.0013176.</citation>
    <PMID>20957176</PMID>
  </reference>
  <reference>
    <citation>Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009 Sep 29;4(9):e7181. doi: 10.1371/journal.pone.0007181.</citation>
    <PMID>19787069</PMID>
  </reference>
  <reference>
    <citation>Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 Jul 15;122(14):2242-50. doi: 10.1002/cncr.30058. Epub 2016 May 20.</citation>
    <PMID>27206146</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Yan Li</investigator_full_name>
    <investigator_title>assistant director physician</investigator_title>
  </responsible_party>
  <keyword>oligometacosis</keyword>
  <keyword>anti-angiogenic</keyword>
  <keyword>apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

